15 alternatives ranked by AI visibility score. Category: Long-Read Sequencing.
Pioneer of single-molecule real-time (SMRT) long-read sequencing; Revio system targets clinical and research markets. Guides to $150–$170M FY2025 revenue with 40%+ gross margins.
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (
Insilico Medicine is a clinical-stage biotechnology company founded in 2014 that leverages generative AI for drug discovery and development. Headquartered in Boston with offices in
Finch Therapeutics is a clinical-stage biotechnology company founded in 2015 that develops microbiome medicines targeting the relationship between the gut microbiome and systemic d
Cognito Therapeutics is developing a non-pharmacological treatment for Alzheimer's disease using coordinated gamma-frequency light and sound stimulation — a technology called senso
Umoja Biopharma is developing an in vivo CAR-T cell therapy platform that circumvents the costly and time-consuming ex vivo manufacturing process that limits current CAR-T therapie
Microbiotica applies genomics and machine learning to map the gut microbiome's causal role in disease, then develops live biotherapeutic products (LBPs) targeting the specific bact
Beam Therapeutics is a genetic medicines company founded in 2017 by base editing pioneers David Liu, J. Keith Joung, and Feng Zhang, having raised over $600M and gone public on Nas